Please login to the form below

Not currently logged in
Email:
Password:

Argenx

This page shows the latest Argenx news and features for those working in and with pharma, biotech and healthcare.

AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal

AbbVie adds to cancer portfolio with $9.8bn Stemcentrx deal

Since then it has signed a series of other agreements to boost its cancer pipeline, including most recently a $685m license deal for an immuno-oncology drug developed by Argenx.

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch April 2016 Deal Watch April 2016

    CytomX leads. Argenx undertakes R&D until IND, AbbVie thereafter it option exercised. ... However the argenx deal is an option not a license and has lower royalty rates.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics